132 related articles for article (PubMed ID: 7624956)
21. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
22. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Korninger C; Collen D
Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
[TBL] [Abstract][Full Text] [Related]
23. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation.
Segal H; Cottam S; Potter D; Hunt BJ
Hepatology; 1997 Mar; 25(3):683-8. PubMed ID: 9049219
[TBL] [Abstract][Full Text] [Related]
24. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
25. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
26. Impaired fibrinolytic potential related to elevated alpha1-proteinase inhibitor levels in patients with pulmonary thromboembolism.
Gombás J; Kolev K; Tarján E; Machovich R
Ann Hematol; 2004 Dec; 83(12):759-63. PubMed ID: 15316758
[TBL] [Abstract][Full Text] [Related]
27. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
30. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
31. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
32. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
33. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect.
Molenaar IQ; Legnani C; Groenland TH; Palareti G; Begliomini B; Terpstra OT; Porte RJ
Liver Transpl; 2001 Oct; 7(10):896-903. PubMed ID: 11679989
[TBL] [Abstract][Full Text] [Related]
34. Tissue-type plasminogen activator (t-PA) and dilute blood clot lysis time in nephrotic patients.
Cucuianu MP; Rus HG; Roman S; Mărcuşu C; Spînu C; Manasia M; Niculescu F
Thromb Haemost; 1989 Apr; 61(2):270-4. PubMed ID: 2501897
[TBL] [Abstract][Full Text] [Related]
35. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
36. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
Gerding PA; Essex-Sorlie D; Vasaune S; Yack R
Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
[TBL] [Abstract][Full Text] [Related]
37. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
38. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
[TBL] [Abstract][Full Text] [Related]
39. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
[TBL] [Abstract][Full Text] [Related]
40. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
